Division of Health Policy and Insurance Research
@healthpolicydpm.bsky.social
A research division in @deptpopmed.bsky.social conducting rigorous, evidence-based studies of key health policies. Passionate about improving health of the most vulnerable.
#ICYMI!: #HarvardMedicalSchool & #HPI researcher, Steven Soumerai, alongside #UPenn, #USydney, #NortheasternU, and #LSE researchers found large reductions in pediatric mental health care following 2003 FDA Black Box Warnings. Read the article here: bit.ly/3Y1PbSm
April 1, 2025 at 7:42 PM
#ICYMI!: #HarvardMedicalSchool & #HPI researcher, Steven Soumerai, alongside #UPenn, #USydney, #NortheasternU, and #LSE researchers found large reductions in pediatric mental health care following 2003 FDA Black Box Warnings. Read the article here: bit.ly/3Y1PbSm
#ICYMI📢 An analysis published in the #theBMJ by #HPI's #AnitaKWagner and colleagues argues that drug regulatory agencies should improve their oversight and information on new drugs. Read what they found here!: www.bmj.com/content/387/...
March 27, 2025 at 1:59 PM
#ICYMI📢 An analysis published in the #theBMJ by #HPI's #AnitaKWagner and colleagues argues that drug regulatory agencies should improve their oversight and information on new drugs. Read what they found here!: www.bmj.com/content/387/...
#ICYMI! #HPI, #Duke, and #USydney researchers studied the effects of adopting a preventive drug list on medication costs and disparities by income. Read what they found here: diabetesjournals.org/care/article...
March 24, 2025 at 9:52 PM
#ICYMI! #HPI, #Duke, and #USydney researchers studied the effects of adopting a preventive drug list on medication costs and disparities by income. Read what they found here: diabetesjournals.org/care/article...
📢#ICYMI! #HPI and #BIDMC_OBGYN researchers examined the financial impact of withdrawn PARP inhibitor treatments for withdarwn ovarian cancer indications. Read the full article here!: valueinhealthjournal.com/article/S109...
March 19, 2025 at 5:13 PM
📢#ICYMI! #HPI and #BIDMC_OBGYN researchers examined the financial impact of withdrawn PARP inhibitor treatments for withdarwn ovarian cancer indications. Read the full article here!: valueinhealthjournal.com/article/S109...